, anti-PD1 in less severe forms of melanoma in the future could also unveil a long-term impact of AKI episodes, Conflict of interest: None, vol.18, p.6

F. Inca--les-cancers-en, , 2019.

T. Achkar and A. A. Tarhini, The use of immunotherapy in the treatment of melanoma, J Hematol Oncol, vol.10, 2017.

I. Lugowska, P. Teterycz, and P. Rutkowski, Immunotherapy of melanoma, Contemp Oncol (Pozn), vol.22, issue.1A, pp.61-68, 2018.

R. M. Poole, Pembrolizumab: first global approval, Drugs, vol.74, issue.16, pp.1973-81, 2014.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in Previously Untreated Melanoma without BRAF Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015.

J. Larkin, C. D. Lao, W. J. Urba, D. F. Mcdermott, C. Horak et al., Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials, JAMA Oncol, vol.1, issue.4, pp.433-473, 2015.

C. Robert, A. Ribas, J. D. Wolchok, F. S. Hodi, O. Hamid et al., Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet, vol.384, pp.1109-1126, 2014.

A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid et al., Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology, vol.16, pp.908-926, 2015.

J. Weber, M. Mandala, D. Vecchio, M. Gogas, H. J. Arance et al., Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma, New England Journal of Medicine, vol.377, issue.19, pp.1824-1859, 2009.

A. Eggermont, C. U. Blank, M. Mandala, G. V. Long, V. Atkinson et al., Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma, New England Journal of Medicine, vol.378, pp.1789-801, 2018.

L. Hofmann, A. Forschner, C. Loquai, S. M. Goldinger, L. Zimmer et al., Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy, Eur J Cancer, vol.60, pp.190-209, 2016.

P. Wang, Y. Chen, S. Song, T. Wang, J. Li et al., Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol, vol.8, 2017.

R. Wanchoo, S. Karam, N. N. Uppal, V. S. Barta, G. Deray et al., Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review, AJN, vol.45, issue.2, pp.160-169, 2017.

M. Espi, C. Teuma, G. Basse, M. Nouvier, D. Maillet et al., NToxicité rénale des immunothérapies : résultats préliminaires de l'étude ImmuNoTox. Néphrologie & Thérapeutique, vol.14, p.248, 2018.

M. E. Sise, H. Seethapathy, and K. L. Reynolds, Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. The Oncologist, 2019.

H. Izzedine and M. A. Perazella, Anticancer Drug-Induced Acute Kidney Injury. Kidney Int Rep, vol.2, pp.504-518, 2017.

S. Herz, T. Höfer, M. Papapanagiotou, J. C. Leyh, S. Meyenburg et al., Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient, Eur J Cancer, vol.67, pp.66-72, 2016.

T. Takenaka, Y. Kawai, and T. Amano, Immune checkpoint therapy in proteinuric kidney disease, European Journal of Cancer, vol.95, pp.120-122, 2018.

F. B. Cortazar, K. A. Marrone, M. L. Troxell, K. M. Ralto, M. P. Hoenig et al., Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, vol.90, issue.3, pp.638-685, 2016.

A. C. Shirali, M. A. Perazella, and S. Gettinger, Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients, American Journal of Kidney Diseases, vol.68, issue.2, pp.287-91, 2016.

H. Izzedine, C. Mateus, C. Boutros, C. Robert, P. Rouvier et al., Renal effects of immune checkpoint inhibitors, Nephrology Dialysis Transplantation, p.382, 2016.

K. Jung, X. Zeng, and M. Bilusic, Nivolumab-associated acute glomerulonephritis: a case report and literature review, BMC Nephrol, vol.17, 2016.

S. Kishi, A case of IgA nephropathy after Nivolumab Therapy

R. A. Daanen, R. Maas, R. Koornstra, E. J. Steenbergen, C. Van-herpen et al., Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report, J Immunother, vol.40, issue.9, pp.345-353, 2017.

O. Mamlouk, U. Selamet, S. Machado, M. Abdelrahim, W. F. Glass et al., Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: singlecenter experience, J Immunother Cancer, vol.7, 2019.

H. Izzedine, A. Mathian, S. Champiat, C. Picard, C. Mateus et al., Renal toxicities associated with pembrolizumab, Clin Kidney J, vol.12, issue.1, pp.81-89, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02155026

J. W. Vandiver, Z. Singer, and C. Harshberger, Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab, Target Oncol, vol.11, issue.4, pp.553-559, 2016.

N. Murakami, S. Motwani, and L. V. Riella, Renal Complications of Immune Checkpoint Blockade, Curr Probl Cancer, vol.41, issue.2, pp.100-110, 2017.

. Fda and . Fda, , 2018.

A. S. Betof, R. D. Nipp, A. Giobbie-hurder, R. Johnpulle, K. Rubin et al., Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma, Oncologist, vol.22, issue.8, pp.963-71, 2017.

J. L. Mcquade, C. R. Daniel, K. R. Hess, C. Mak, D. Y. Wang et al., The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, Lancet Oncol, vol.19, issue.3, pp.310-332, 2018.

E. G. Aguilar and W. J. Murphy, Obesity induced T cell dysfunction and implications for cancer immunotherapy, Curr Opin Immunol, vol.51, pp.181-187, 2018.

R. J. Canter, C. T. Le, J. Beerthuijzen, and W. J. Murphy, Obesity as an immune-modifying factor in cancer immunotherapy, J Leukoc Biol, vol.104, issue.3, pp.487-97, 2018.

C. Sanmiguel, A. Gupta, and E. A. Mayer, Gut Microbiome and Obesity: A Plausible Explanation for Obesity. Curr Obes Rep, vol.4, pp.250-61, 2015.

L. Genser, C. Poitou, É. Brot-laroche, M. Rousset, J. Vaillant et al., Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?
URL : https://hal.archives-ouvertes.fr/hal-01331313

, Med Sci (Paris), vol.32, issue.5, pp.461-470, 2016.

V. Matson, J. Fessler, R. Bao, T. Chongsuwat, Y. Zha et al., The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science, vol.359, issue.6371, pp.104-112, 201805.

V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews et al., Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, vol.359, issue.6371, pp.97-103, 2018.

K. Homicsko, G. Richtig, F. Tuchmann, Z. Tsourti, D. Hanahan et al., LBA2Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients, Ann Oncol [Internet], vol.29, issue.suppl_10, 2018.

S. Mukherjee, S. Ibrahimi, B. Khalid, D. Roman, D. Zhao et al., Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study, Journal of Oncology Pharmacy Practice, vol.25, issue.3, pp.762-766, 2019.

A. Trabolsi, M. Winter, and E. Rodriguez, Proton pump inhibitors and response to immune checkpoint inhibitors: Single center study. JCO, vol.37, pp.14092-14092, 2019.

K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin et al., Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer, JCO, vol.36, issue.28, pp.2872-2880, 2018.

S. Scott, Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab -Journal of Thoracic Oncology, 2019.

H. Abu-sbeih, T. Tang, F. S. Ali, D. H. Johnson, W. Qiao et al., The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes, Journal of Immunotherapy and Precision Oncology, vol.1, issue.1, p.7, 2018.

N. Okada, H. Kawazoe, K. Takechi, Y. Matsudate, R. Utsunomiya et al., Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study, Clinical Therapeutics, vol.41, issue.1, pp.59-67, 2019.

F. Tables and . Legends,

, Baseline characteristics of the two groups: AKI versus control (NA: not available, missing data)

, Kaplan Meier Survival curve in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab)

, Overall survival; 2B. Survival considering the occurrence of AKI, p.2

, Kaplan Meier overall survival curve in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab), univariate Cox regression analysis: 3A. Anti-PD1: line number of treatments. 3B. BMI. 3C. Corticosteroids as a baseline treatment

, Kaplan Meier survival curve considering the occurrence of AKI in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab), p.univariate

, Cox regression analysis: 4A. ACE inhibitors or AIIRA. 4B. Chronic kidney disease 4C. Corticosteroids as a baseline treatment 4D

, Kaplan Meier survival curve considering a composite primary outcome (AKI or death) in patients treated for a metastatic melanoma with anti-PD1 antibodies (Nivolumab or Pembrolizumab)

. B. 5b and . 5c, Corticosteroids as a baseline treatment 5D. PPI as a baseline treatment

, 5%) Dyslipidemia 55/233 (23.6%) NA : 6/239 (2,5%) Autoimmune Disease, .9%) Corticosteroid daily dose (mg) -Mean (range) of anti-PD1 (mg) : -Mean (range), pp.80-16980

, BMI (kg/m2): -Mean (range)

, Hypertension

, Corticosteroid, vol.12, issue.41

, Corticosteroid daily dose (mg): -Mean (range)

, Melanoma staging (AJCC) : -IIIB -IIIC -IV

A. Used,

, N cycles of anti-PD1: -Mean (range)

, Cumulated doses of anti-PD1 (mg): -Mean (range) -Median